Exploring the Anticancer Effects of Xianliu Jieduan Fang on Colitis‐Associated Colorectal Cancer Through Network Pharmacology and Experimental Validation
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Fang-Lan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anorectal, Shenzhen Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Colitis-Associated Neoplasms, Antineoplastic Agents, Colorectal Neoplasms. Die Arbeit nennt 56 Literaturangaben. Gefördert von: Shenzhen High-level Hospital Construction Fund, Shenzhen Science and Technology Program.
Abstract (Originalsprache)
This study evaluated the therapeutic effects of Xianliu Jieduan Fang (XLJDF) on colitis‐associated colorectal cancer (CAC) and explored its molecular mechanisms through network pharmacology and experimental validation. Using an AOM/DSS‐induced CAC mouse model, we evaluated XLJDF's efficacy. Active components were identified by UHPLC‐QE‐HRMS. Targets were predicted using SwissTargetPrediction and PubChem, while disease genes were obtained from GeneCards, DisGeNET, and TTD. Core targets and pathways were analyzed via Cytoscape and Metascape. Mechanisms were validated through molecular docking and experiments. XLJDF improved colon pathology and identified 68 active compounds, including nine key components like Kaempferol and Luteolin. Network analysis revealed 959 targets with 29 core genes (AKT1, CTNNB1, GSK3B, etc.). KEGG analysis showed XLJDF primarily acts through Wnt signaling, regulating apoptosis and cell migration. Experimental validation confirmed XLJDF inhibits Wnt/β‐catenin pathway by preventing GSK3β inactivation. XLJDF exerts anti‐CAC effects via a multi‐component, multi‐target network. Our study identifies key active compounds and demonstrates that XLJDF suppresses the Wnt/β‐catenin pathway by preventing GSK3β inactivation, thereby inhibiting β‐catenin stabilization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anorectal, Shenzhen Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, China.
- The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
ORCID-Profile: Xiang-Dong Zhao
Förderung
- Shenzhen High-level Hospital Construction Fund
- Shenzhen Science and Technology Program
Zitieren
APA
Li, F. L., Wang, B. B., Zeng, K. F., Chen, H. Y., Wu, X. H., Wang, Y., Lin, H. C., Li, W. L., & Zhao, X. D. (2025). Exploring the Anticancer Effects of Xianliu Jieduan Fang on Colitis‐Associated Colorectal Cancer Through Network Pharmacology and Experimental Validation. Biomedical Chromatography. https://doi.org/10.1002/bmc.70102
Vancouver
Li FL, Wang BB, Zeng KF, Chen HY, Wu XH, Wang Y, et al. Exploring the Anticancer Effects of Xianliu Jieduan Fang on Colitis‐Associated Colorectal Cancer Through Network Pharmacology and Experimental Validation. Biomedical Chromatography. 2025. doi:10.1002/bmc.70102
BibTeX
@article{Li2025,
author = {Li, Fang-Lan and Wang, Bei-Bei and Zeng, Ke-Feng and Chen, Hao-Yang and Wu, Xi-Hua and Wang, Yun and Lin, Hong-Cheng and Li, Wei-Lin and Zhao, Xiang-Dong},
title = {Exploring the Anticancer Effects of Xianliu Jieduan Fang on Colitis‐Associated Colorectal Cancer Through Network Pharmacology and Experimental Validation},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70102}
}
EUVIMED